Brigitte Kaiser
Friedrich Schiller University Jena
Center for Vascular Biology and Medicine Erfurt
Germany
Name/email consistency: high
- DX-9065a, a direct inhibitor of factor Xa. Kaiser, B. Cardiovasc. Drug. Rev (2003)
- DX-9065a Daiichi. Kaiser, B. Curr. Opin. Investig. Drugs (2003)
- Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Kaiser, B., Hoppensteadt, D.A., Fareed, J. Expert. Opin. Investig. Drugs (2001)
- A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats. Kaiser, B., Paintz, M., Scholz, O., Kunitada, S., Fareed, J. Thromb. Res. (2000)
- Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Kaiser, B., Jeske, W., Walenga, J.M., Fareed, J. Blood Coagul. Fibrinolysis (1999)
- Synthetic and recombinant antithrombin drugs. Kaiser, B., Callas, D., Walenga, J.M., Fareed, J. Expert. Opin. Investig. Drugs (1998)
- Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders. Kaiser, B., Hoppensteadt, D.H., Fareed, J. Expert. Opin. Investig. Drugs (1998)
- A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans. Kaiser, B., Glusa, E., Hoppensteadt, D.A., Breddin, H.K., Amiral, J., Fareed, J. Blood Coagul. Fibrinolysis (1998)
- In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. Kaiser, B., Jeske, W., Hoppensteadt, D.H., Walenga, J.M., Drohan, W., Fareed, J. Thromb. Res. (1997)